LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Arrotex Pharmaceuticals Pty Ltd. ("Arrotex") today announced an exclusive license and commercialization agreement for Arrotex to register and commercialize VIZZ™ for the treatment of presbyopia in Australia and New Zealand. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. Arrotex is Australia’s largest and most diversified pharmaceutical company, offering the most extensive range of prescription medicines across therapeutic areas.

Under the terms of the agreement, LENZ will receive an upfront payment and a significant profit share of gross margin from product sales. Arrotex will obtain exclusive commercialization rights for VIZZ for the treatment of presbyopia in Australia and New Zealand.